OBJECTIVE: An unsettled issue is the use of thrombolytic agents in patients with acute pulmonary embolism (PE) who are hemodynamically stable but have right ventricular (RV) enlargement. We assessed the in-hospital mortality of hemodynamically stable patients with PE and RV enlargement. METHODS: Patients were enrolled in the Prospective Investigation of Pulmonary Embolism Diagnosis II. Exclusions included shock, critical illness, ventilatory support, or myocardial infarction within 1 month, and ventricular tachycardia or ventricular fibrillation within 24 hours. We evaluated the ratio of the RV minor axis to the left ventricular minor axis measured on transverse images during computed tomographic angiography. RESULTS: Among 76 patients with RV enlargement treated with anticoagulants and/or inferior vena cava filters, in-hospital deaths from PE were 0 of 76 (0%) and all-cause mortality was 2 of 76 (2.6%). No septal motion abnormality was observed in 49 patients (64%), septal flattening was observed in 25 patients (33%), and septal deviation was observed in 2 patients (3%). No patients required ventilatory support, vasopressor therapy, rescue thrombolytic therapy, or catheter embolectomy. There were no in-hospital deaths caused by PE. There was no difference in all-cause mortality between patients with and without RV enlargement (relative risk=1.04). CONCLUSION: In-hospital prognosis is good in patients with PE and RV enlargement if they are not in shock, acutely ill, or on ventilatory support, or had a recent myocardial infarction or life-threatening arrhythmia. RV enlargement alone in patients with PE, therefore, does not seem to indicate a poor prognosis or the need for thrombolytic therapy.
OBJECTIVE: An unsettled issue is the use of thrombolytic agents in patients with acute pulmonary embolism (PE) who are hemodynamically stable but have right ventricular (RV) enlargement. We assessed the in-hospital mortality of hemodynamically stable patients with PE and RV enlargement. METHODS:Patients were enrolled in the Prospective Investigation of Pulmonary Embolism Diagnosis II. Exclusions included shock, critical illness, ventilatory support, or myocardial infarction within 1 month, and ventricular tachycardia or ventricular fibrillation within 24 hours. We evaluated the ratio of the RV minor axis to the left ventricular minor axis measured on transverse images during computed tomographic angiography. RESULTS: Among 76 patients with RV enlargement treated with anticoagulants and/or inferior vena cava filters, in-hospital deaths from PE were 0 of 76 (0%) and all-cause mortality was 2 of 76 (2.6%). No septal motion abnormality was observed in 49 patients (64%), septal flattening was observed in 25 patients (33%), and septal deviation was observed in 2 patients (3%). No patients required ventilatory support, vasopressor therapy, rescue thrombolytic therapy, or catheter embolectomy. There were no in-hospital deaths caused by PE. There was no difference in all-cause mortality between patients with and without RV enlargement (relative risk=1.04). CONCLUSION: In-hospital prognosis is good in patients with PE and RV enlargement if they are not in shock, acutely ill, or on ventilatory support, or had a recent myocardial infarction or life-threatening arrhythmia. RV enlargement alone in patients with PE, therefore, does not seem to indicate a poor prognosis or the need for thrombolytic therapy.
Authors: Paul D Stein; Sarah E Fowler; Lawrence R Goodman; Alexander Gottschalk; Charles A Hales; Russell D Hull; Kenneth V Leeper; John Popovich; Deborah A Quinn; Thomas A Sos; H Dirk Sostman; Victor F Tapson; Thomas W Wakefield; John G Weg; Pamela K Woodard Journal: N Engl J Med Date: 2006-06-01 Impact factor: 91.245
Authors: Rishi Sukhija; Wilbert S Aronow; Jooyun Lee; Priyanka Kakar; John A McClung; James A Levy; Robert N Belkin Journal: Am J Cardiol Date: 2005-03-01 Impact factor: 2.778
Authors: Marzia Leacche; Daniel Unic; Samuel Z Goldhaber; James D Rawn; Sary F Aranki; Gregory S Couper; Tomislav Mihaljevic; Robert J Rizzo; Lawrence H Cohn; Lishan Aklog; John G Byrne Journal: J Thorac Cardiovasc Surg Date: 2005-05 Impact factor: 5.209
Authors: Rutger W van der Meer; Peter M T Pattynama; Marco J L van Strijen; Annette A van den Berg-Huijsmans; Ieneke J C Hartmann; Hein Putter; Albert de Roos; Menno V Huisman Journal: Radiology Date: 2005-04-21 Impact factor: 11.105
Authors: Benoit Ghaye; Alexandre Ghuysen; Valerie Willems; Bernard Lambermont; Paul Gerard; Vincent D'Orio; Pierre Alain Gevenois; Robert F Dondelinger Journal: Radiology Date: 2006-04-07 Impact factor: 11.105
Authors: U Joseph Schoepf; Nils Kucher; Florian Kipfmueller; Rene Quiroz; Philip Costello; Samuel Z Goldhaber Journal: Circulation Date: 2004-11-08 Impact factor: 29.690
Authors: David Jiménez; José Luis Lobo; Manuel Monreal; Remedios Otero; Roger D Yusen Journal: J Thromb Thrombolysis Date: 2012-08 Impact factor: 2.300
Authors: Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Paul D Stein; Fadi Matta; Abdo Y Yaekoub; Lawrence R Goodman; H Dirk Sostman; John G Weg; Charles A Hales; Russell D Hull; Kenneth V Leeper; Afzal Beemath; Ibrahim M Saeed; Pamela K Woodard Journal: J Thromb Thrombolysis Date: 2009-03-27 Impact factor: 2.300
Authors: Kanako K Kumamaru; Andetta R Hunsaker; Arash Bedayat; Shigeyoshi Soga; Jason Signorelli; Kimberly Adams; Nicole Wake; Michael T Lu; Frank J Rybicki Journal: Int J Cardiovasc Imaging Date: 2011-06-14 Impact factor: 2.357
Authors: Paul D Stein; H Dirk Sostman; Russell D Hull; Lawrence R Goodman; Kenneth V Leeper; Alexander Gottschalk; Victor F Tapson; Pamela K Woodard Journal: Am J Cardiol Date: 2009-01-24 Impact factor: 2.778
Authors: Luca Masotti; Marc Righini; Nicolas Vuilleumier; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Patrick Ray Journal: Vasc Health Risk Manag Date: 2009-07-14